Application of a Stochastic Simulation–estimation Approach to Optimize Pharmacokinetic Study Design in the Context of Paediatric Extrapolation: A Tool to Support Decision-making by Drug Sponsors and Regulators
Pharmaceutical Research · 2026
DOI: 10.1007/s11095-026-04033-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Happy Phanio Djokoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology Research Unit, Faculty of Medicine, University of Namur, Rue de Bruxelles 51, B-5000, Namur, Belgium. Hauptthemen laut MEDLINE: Drug Development, Research Design, Pharmacokinetics. Die Arbeit nennt 38 Literaturangaben. Gefördert von: HORIZON EUROPE Framework Programme.
Abstract (Originalsprache)
BACKGROUND: Extrapolation-based approaches are widely used in paediatric drug development. These often rely on pharmacokinetic (PK) matching to support inference on the benefit-risk balance (BRB). PK-based extrapolation requires generation of PK data in children. Given ethical and practical challenges in paediatric trials, collected data must be relevant and informative. METHODS: This work proposes a stochastic simulation-estimation (SSE) approach to optimise key study design factors (number of patients, samples per patient, and sampling times) for paediatric PK studies in extrapolation contexts. Using three illustrative case studies a subcutaneous monoclonal antibody (mosunetuzumab) and two small molecules with intravenous (meropenem) and oral (olanzapine) administration we demonstrate how SSE can be used in paediatric drug development and how it meets regulatory requirements. RESULTS: SSE enabled prospective optimisation of paediatric study designs using adult drug development data. For each case drug, designs were identified where key model parameter imprecision (normalised root mean squared error, NRMSE) remained below 30% and bias (relative bias, RBias) below 20%. CONCLUSIONS: These case studies illustrate how SSE can be used to evaluate paediatric PK study design options in extrapolation settings and provides drug sponsors and regulators with a practical tool to decision-making related to study design optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology and Toxicology Research Unit, Faculty of Medicine, University of Namur, Rue de Bruxelles 51, B-5000, Namur, Belgium.
- Clinical Pharmacology and Toxicology Research Unit, Faculty of Medicine, University of Namur, Rue de Bruxelles 51, B-5000, Namur, Belgium. Flora.musuamba@unamur.be.
- Belgian Federal Agency for Medicines and Health Products, B-1210, Brussels, Belgium. Flora.musuamba@unamur.be.
- Faculté de Sciences Pharmaceutiques, Université de Lubumbashi, Lubumbashi, Democratic Republic of the Congo. Flora.musuamba@unamur.be.
Förderung
- HORIZON EUROPE Framework Programme
Zitieren
APA
Djokoto, H. P., Ernst, L., Dogné, J. M., & Musuamba, F. T. (2026). Application of a Stochastic Simulation–estimation Approach to Optimize Pharmacokinetic Study Design in the Context of Paediatric Extrapolation: A Tool to Support Decision-making by Drug Sponsors and Regulators. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04033-3
Vancouver
Djokoto HP, Ernst L, Dogné JM, Musuamba FT. Application of a Stochastic Simulation–estimation Approach to Optimize Pharmacokinetic Study Design in the Context of Paediatric Extrapolation: A Tool to Support Decision-making by Drug Sponsors and Regulators. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04033-3
BibTeX
@article{Djokoto2026,
author = {Djokoto, Happy Phanio and Ernst, Lara and Dogné, Jean-Michel and Musuamba, Flora T},
title = {Application of a Stochastic Simulation–estimation Approach to Optimize Pharmacokinetic Study Design in the Context of Paediatric Extrapolation: A Tool to Support Decision-making by Drug Sponsors and Regulators},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04033-3}
}
EUVIMED